Effects of statins on the risk of hepatocellular carcinoma

Pejman G. Mansourian, Masato Yoneda, M. Krishna Rao, Fernando J. Martinez, Emmanuel Thomas, Eugene R Schiff

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer morbidity and mortality worldwide and is one of the few cancers that is increasing in incidence. This cancer often arises in the setting of hepatic cirrhosis; however, it can also occur in patients with chronic hepatitis B virus infection without cirrhosis. Statins have been used for many years for the prevention and treatment of cardiovascular disease. Based on recent meta-analyses, these lipid-lowering agents are now being investigated for a class effect observed in the prevention of carcinogenesis. There are robust data suggesting that statins can alter biochemical pathways involved in tumorigenesis and cell survival and, thus, have a protective effect by reducing the risk of development of several types of cancer. In recent years, several studies have demonstrated that statins also can specifically decrease the risk of HCC development. Because statins are underutilized in patients with preexisting liver disease, understanding the role of statins in the prevention of HCC is important, and changes in practice guidelines supporting the use of statins as chemoprotective agents may be warranted.

Original languageEnglish
Pages (from-to)417-426
Number of pages10
JournalGastroenterology and Hepatology
Volume10
Issue number7
StatePublished - Jan 1 2014

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hepatocellular Carcinoma
Neoplasms
Carcinogenesis
Preexisting Condition Coverage
Chronic Hepatitis B
Virus Diseases
Practice Guidelines
Hepatitis B virus
Liver Cirrhosis
Meta-Analysis
Liver Diseases
Cell Survival
Fibrosis
Cardiovascular Diseases
Morbidity
Lipids
Mortality
Incidence

Keywords

  • Cirrhosis
  • Hepatitis B
  • Hepatitis C
  • Hepatocellular carcinoma
  • HMG-CoA reductase
  • Nonalcoholic steatohepatitis
  • Statins

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Mansourian, P. G., Yoneda, M., Rao, M. K., Martinez, F. J., Thomas, E., & Schiff, E. R. (2014). Effects of statins on the risk of hepatocellular carcinoma. Gastroenterology and Hepatology, 10(7), 417-426.

Effects of statins on the risk of hepatocellular carcinoma. / Mansourian, Pejman G.; Yoneda, Masato; Rao, M. Krishna; Martinez, Fernando J.; Thomas, Emmanuel; Schiff, Eugene R.

In: Gastroenterology and Hepatology, Vol. 10, No. 7, 01.01.2014, p. 417-426.

Research output: Contribution to journalArticle

Mansourian, PG, Yoneda, M, Rao, MK, Martinez, FJ, Thomas, E & Schiff, ER 2014, 'Effects of statins on the risk of hepatocellular carcinoma', Gastroenterology and Hepatology, vol. 10, no. 7, pp. 417-426.
Mansourian PG, Yoneda M, Rao MK, Martinez FJ, Thomas E, Schiff ER. Effects of statins on the risk of hepatocellular carcinoma. Gastroenterology and Hepatology. 2014 Jan 1;10(7):417-426.
Mansourian, Pejman G. ; Yoneda, Masato ; Rao, M. Krishna ; Martinez, Fernando J. ; Thomas, Emmanuel ; Schiff, Eugene R. / Effects of statins on the risk of hepatocellular carcinoma. In: Gastroenterology and Hepatology. 2014 ; Vol. 10, No. 7. pp. 417-426.
@article{75f87f6be667481692509539d1323e8e,
title = "Effects of statins on the risk of hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) is one of the leading causes of cancer morbidity and mortality worldwide and is one of the few cancers that is increasing in incidence. This cancer often arises in the setting of hepatic cirrhosis; however, it can also occur in patients with chronic hepatitis B virus infection without cirrhosis. Statins have been used for many years for the prevention and treatment of cardiovascular disease. Based on recent meta-analyses, these lipid-lowering agents are now being investigated for a class effect observed in the prevention of carcinogenesis. There are robust data suggesting that statins can alter biochemical pathways involved in tumorigenesis and cell survival and, thus, have a protective effect by reducing the risk of development of several types of cancer. In recent years, several studies have demonstrated that statins also can specifically decrease the risk of HCC development. Because statins are underutilized in patients with preexisting liver disease, understanding the role of statins in the prevention of HCC is important, and changes in practice guidelines supporting the use of statins as chemoprotective agents may be warranted.",
keywords = "Cirrhosis, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, HMG-CoA reductase, Nonalcoholic steatohepatitis, Statins",
author = "Mansourian, {Pejman G.} and Masato Yoneda and Rao, {M. Krishna} and Martinez, {Fernando J.} and Emmanuel Thomas and Schiff, {Eugene R}",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "10",
pages = "417--426",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "7",

}

TY - JOUR

T1 - Effects of statins on the risk of hepatocellular carcinoma

AU - Mansourian, Pejman G.

AU - Yoneda, Masato

AU - Rao, M. Krishna

AU - Martinez, Fernando J.

AU - Thomas, Emmanuel

AU - Schiff, Eugene R

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Hepatocellular carcinoma (HCC) is one of the leading causes of cancer morbidity and mortality worldwide and is one of the few cancers that is increasing in incidence. This cancer often arises in the setting of hepatic cirrhosis; however, it can also occur in patients with chronic hepatitis B virus infection without cirrhosis. Statins have been used for many years for the prevention and treatment of cardiovascular disease. Based on recent meta-analyses, these lipid-lowering agents are now being investigated for a class effect observed in the prevention of carcinogenesis. There are robust data suggesting that statins can alter biochemical pathways involved in tumorigenesis and cell survival and, thus, have a protective effect by reducing the risk of development of several types of cancer. In recent years, several studies have demonstrated that statins also can specifically decrease the risk of HCC development. Because statins are underutilized in patients with preexisting liver disease, understanding the role of statins in the prevention of HCC is important, and changes in practice guidelines supporting the use of statins as chemoprotective agents may be warranted.

AB - Hepatocellular carcinoma (HCC) is one of the leading causes of cancer morbidity and mortality worldwide and is one of the few cancers that is increasing in incidence. This cancer often arises in the setting of hepatic cirrhosis; however, it can also occur in patients with chronic hepatitis B virus infection without cirrhosis. Statins have been used for many years for the prevention and treatment of cardiovascular disease. Based on recent meta-analyses, these lipid-lowering agents are now being investigated for a class effect observed in the prevention of carcinogenesis. There are robust data suggesting that statins can alter biochemical pathways involved in tumorigenesis and cell survival and, thus, have a protective effect by reducing the risk of development of several types of cancer. In recent years, several studies have demonstrated that statins also can specifically decrease the risk of HCC development. Because statins are underutilized in patients with preexisting liver disease, understanding the role of statins in the prevention of HCC is important, and changes in practice guidelines supporting the use of statins as chemoprotective agents may be warranted.

KW - Cirrhosis

KW - Hepatitis B

KW - Hepatitis C

KW - Hepatocellular carcinoma

KW - HMG-CoA reductase

KW - Nonalcoholic steatohepatitis

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84904995899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904995899&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84904995899

VL - 10

SP - 417

EP - 426

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

SN - 1554-7914

IS - 7

ER -